It is planned to prospectively collect, collate and report real-world clinical data of BSTS patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and survival information of these patients, in order to provide reference for clinical treatment and research of this type of tumor.
Eligibility
Sex
ALL
Min age
6 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria:
All ages, male and female.
The pathological diagnosis of BSTS in our hospital was a subtype.
Has received at least one hospitalization in this hospital.
The target lesions could be evaluated according to the efficacy evaluation criteria of solid tumor (RECIST; Version 1.1) Measure diameter changes.
Exclusion Criteria:
No definite pathology.
Primary outcome measure(s)
Overall survival — Up to approximately 120months Pathologically confirmed events leading to death
6/5000 Progression-free survival — Up to approximately 48months The time from the first use of the treatment to the observation of disease progression
Trial sites (1)
Facility
City
Region
Status
Department of Bone and Soft Tissue ,Henan Cancer Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.